Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G, Gigli F, Parma G, Lapresa M, Derio S, Palaia I, Colombo N. Caruso G, et al. Among authors: palaia i. Int J Gynecol Cancer. 2023 Apr 3;33(4):598-606. doi: 10.1136/ijgc-2022-004190. Int J Gynecol Cancer. 2023. PMID: 36707087 Review.
Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications.
Benedetti-Panici P, Perniola G, Marchetti C, Pernice M, Donfrancesco C, Di Donato V, Tomao F, Palaia I, Graziano M, Basile S, Bellati F. Benedetti-Panici P, et al. Among authors: palaia i. Int J Gynecol Cancer. 2012 Jul;22(6):1069-74. doi: 10.1097/IGC.0b013e31825736b2. Int J Gynecol Cancer. 2012. PMID: 22665042 Clinical Trial.
Recurrent Ovarian Cancer: The Role of Radiation Therapy.
De Felice F, Marchetti C, Di Mino A, Palaia I, Benevento I, Musella A, Musio D, Tombolini V. De Felice F, et al. Among authors: palaia i. Int J Gynecol Cancer. 2017 May;27(4):690-695. doi: 10.1097/IGC.0000000000000958. Int J Gynecol Cancer. 2017. PMID: 28399032 Review.
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Tomao F, et al. Among authors: palaia i. Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9. Cancer Treat Rev. 2019. PMID: 31629204 Review.
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Musacchio L, Boccia SM, Caruso G, Santangelo G, Fischetti M, Tomao F, Perniola G, Palaia I, Muzii L, Pignata S, Benedetti Panici P, Di Donato V. Musacchio L, et al. Among authors: palaia i. J Clin Med. 2020 Jun 3;9(6):1721. doi: 10.3390/jcm9061721. J Clin Med. 2020. PMID: 32503218 Free PMC article. Review.
The role of the sentinel lymph node in vulvar cancer.
Giannini A, D'''''Oria O, Santangelo G, Allegrini CM, Caruso G, Di Pinto A, Perniola G, Palaia I, Monti M, Muzii L, Benedetti Panici P, Di Donato V. Giannini A, et al. Among authors: palaia i. Minerva Ginecol. 2020 Dec;72(6):361-366. doi: 10.23736/S0026-4784.20.04601-8. Epub 2020 Jul 17. Minerva Ginecol. 2020. PMID: 32677774
First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.
Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. Tomao F, et al. Among authors: palaia i. Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020. Cancer Manag Res. 2020. PMID: 32765062 Free PMC article. Review.
199 results